{"title": null, "author": null, "url": null, "hostname": null, "description": "Revista Finlay", "sitename": null, "date": "2023-03-24", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "|Las autoridades sanitarias de Estados Unidos aprobaron la vacuna Gardasil para prevenir el c\u00e1ncer anal y las lesiones precancerosas asociadas por el virus del papiloma humano (VPH) de los tipos 6, 11, 16 y 18 para personas con edades entre 9 y 26 a\u00f1os.\n|\nGardasil ya est\u00e1 aprobada para la prevenci\u00f3n del c\u00e1ncer cervicouterino y las lesiones precancerosas asociadas causadas por el VPH de los tipos 6, 11, 16, y 18 en f\u00e9minas de ese rango de edad, inform\u00f3 la Administraci\u00f3n de F\u00e1rmacos y Alimentos (FDA).\nTambi\u00e9n est\u00e1 aprobada para la prevenci\u00f3n de las verrugas genitales causadas por los tipos 6 y 11 del VPH, tanto en varones como en hembras.\n\"El tratamiento para el c\u00e1ncer anal es un reto\", se\u00f1al\u00f3 Karen Midthun, directora del Centro para la Evaluaci\u00f3n e Investigaci\u00f3n de Productos Biol\u00f3gicos de la FDA en un comunicado.\nMidthun se\u00f1al\u00f3 que Gardasil \"puede contribuir a reducir el n\u00famero de diagn\u00f3sticos y la consiguiente cirug\u00eda, radioterapia o quimioterapia\" a las que tienen que someterse los pacientes.\nLa FDA se\u00f1al\u00f3 que aunque el c\u00e1ncer anal es raro en la poblaci\u00f3n general, la incidencia va en aumento.\nLa American Cancer Society calcula que cerca de 5300 personas son diagnosticadas con este tipo de c\u00e1ncer cada a\u00f1o en Estados Unidos, con un mayor porcentaje en las hembras que en los varones.\nLas autoridades advierten de que Gardasil no previene el desarrollo de lesiones anales precancerosas asociadas a las infecciones por el VPH que el paciente tiene ya en el momento de la vacunaci\u00f3n.\nWashington, diciembre 23/2010\nFINLAY EN:\nFINLAY CERTIFICADA POR:\nEsta revista \"no aplica\" cargos por publicaci\u00f3n en ninguna etapa del proceso editorial.\nDirecci\u00f3n postal: Calle 51A y Avenida 5 de Septiembre Cienfuegos, Cuba C\u00f3digo postal: 55100.\n[http://www.revfinlay.sld.cu]\nTelefono: +53 43 516602. Telefax: +53 43 517733.\n[amgiraldoni@infomed.sld.cu](mailto:amgiraldoni@infomed.sld.cu)\nISSN: 2221-2434\nRNPS: 5129", "language": null, "image": null, "pagetype": null, "links": ["https://revfinlay.sld.cu/index.php/finlay/information/readers", "https://revfinlay.sld.cu/index.php/finlay/information/authors", "https://revfinlay.sld.cu/index.php/finlay/information/librarians", "https://revfinlay.sld.cu/index.php/finlay/article/view/1214", "https://revfinlay.sld.cu/index.php/finlay/article/view/1206", "https://revfinlay.sld.cu/index.php/finlay/article/view/1235", "https://revfinlay.sld.cu/index.php/finlay/article/view/1255", "https://revfinlay.sld.cu/index.php/finlay/article/view/1232", "https://revfinlay.sld.cu/index.php/finlay/article/view/164", "https://revfinlay.sld.cu/index.php/finlay/article/view/403", "https://revfinlay.sld.cu/index.php/finlay/article/view/39", "https://revfinlay.sld.cu/index.php/finlay/article/view/242", "https://revfinlay.sld.cu/index.php/finlay/article/view/253", "https://revfinlay.sld.cu/index.php/finlay/issue/current/showToc", "https://revfinlay.sld.cu/index.php/finlay/MedisurNavigationPlugin/viewFutureIssue", "https://revfinlay.sld.cu/index.php/finlay/issue/archive", "https://revfinlay.sld.cu/index.php/finlay/search/authors", "https://revfinlay.sld.cu/index.php/finlay/search/titles", "https://revfinlay.sld.cu/index.php/finlay/gateway/plugin/AnnouncementFeedGatewayPlugin/atom", "https://revfinlay.sld.cu/index.php/finlay/gateway/plugin/AnnouncementFeedGatewayPlugin/rss2", "https://revfinlay.sld.cu/index.php/finlay/gateway/plugin/AnnouncementFeedGatewayPlugin/rss", "https://revfinlay.sld.cu/index.php/finlay/gateway/plugin/WebFeedGatewayPlugin/atom", "https://revfinlay.sld.cu/index.php/finlay/gateway/plugin/WebFeedGatewayPlugin/rss2", "https://revfinlay.sld.cu/index.php/finlay/gateway/plugin/WebFeedGatewayPlugin/rss", "https://revfinlay.sld.cu/index.php/finlay/search?subject=accidente%20cerebrovascular", "https://revfinlay.sld.cu/index.php/finlay/search?subject=adolescente", "https://revfinlay.sld.cu/index.php/finlay/search?subject=adulto", "https://revfinlay.sld.cu/index.php/finlay/search?subject=anciano", "https://revfinlay.sld.cu/index.php/finlay/search?subject=atenci%C3%B3n%20primaria%20de%20salud", "https://revfinlay.sld.cu/index.php/finlay/search?subject=cuba", "https://revfinlay.sld.cu/index.php/finlay/search?subject=diabetes%20mellitus", "https://revfinlay.sld.cu/index.php/finlay/search?subject=diabetes%20mellitus%20tipo%202", "https://revfinlay.sld.cu/index.php/finlay/search?subject=diagn%C3%B3stico", "https://revfinlay.sld.cu/index.php/finlay/search?subject=enfermedad%20cr%C3%B3nica", "https://revfinlay.sld.cu/index.php/finlay/search?subject=enfermedades%20cardiovasculares", "https://revfinlay.sld.cu/index.php/finlay/search?subject=factores%20de%20riesgo", "https://revfinlay.sld.cu/index.php/finlay/search?subject=hipertensi%C3%B3n", "https://revfinlay.sld.cu/index.php/finlay/search?subject=informes%20de%20casos", "https://revfinlay.sld.cu/index.php/finlay/search?subject=morbilidad", "https://revfinlay.sld.cu/index.php/finlay/search?subject=mortalidad", "https://revfinlay.sld.cu/index.php/finlay/search?subject=neoplasias%20de%20la%20mama", "https://revfinlay.sld.cu/index.php/finlay/search?subject=obesidad", "https://revfinlay.sld.cu/index.php/finlay/search?subject=prevenci%C3%B3n%20de%20enfermedades", "https://revfinlay.sld.cu/index.php/finlay/search?subject=reporte%20de%20casos", "https://revfinlay.sld.cu/index.php/finlay/search?subject=terap%C3%A9utica", "https://revfinlay.sld.cu/index.php/finlay/index", "https://revfinlay.sld.cu/index.php/finlay/about", "https://revfinlay.sld.cu/index.php/finlay/login", "https://revfinlay.sld.cu/index.php/finlay/user/register", "https://revfinlay.sld.cu/index.php/finlay/search", "https://revfinlay.sld.cu/index.php/finlay/issue/current", "https://revfinlay.sld.cu/index.php/finlay/issue/archive", "https://revfinlay.sld.cu/index.php/finlay/announcement", "http://www.revfinlay.sld.cu/index.php/finlay/about/submissions#onlineSubmissions", "https://revfinlay.sld.cu/index.php/finlay/index", "https://revfinlay.sld.cu/index.php/finlay/announcement", "https://revfinlay.sld.cu/index.php/finlay/announcement/view/22", "http://scholar.google.com.cu/scholar?hl=es&q=Revista+Finlay&btnG=Buscar&lr=&as_sdt=0%2C5", "http://www.doaj.org/doaj?func=openurl&issn=22212434&genre=journal&uiLanguage=en", "http://www.bvscuba.sld.cu/php/level.php?lang=es&component=56&item=63", "http://www.latindex.unam.mx/buscador/ficRev.html?opcion=1&folio=20073", "http://new.medigraphic.com/cgi-bin/publicaciones.cgi?IDREVISTA=294", "http://extranet.who.int/hinari/es/browse_journal_titles.php?j_init=F", "http://scielo.sld.cu/scielo.php?script=sci_serial&pid=2221-2434&lng=es&nrm=iso", "https://www.redib.org/recursos/Serials/Record/oai_revista1086-finlay", "http://science.thomsonreuters.com/cgi-bin/jrnlst/jlresults.cgi?PC=EX&ISSN=2221-2434", "https://www.facebook.com/Finlay-Revista-de-Enfermedades-Cr%C3%B3nicas-320153004349/", "https://twitter.com/revfinlay", "/index.php/finlay/about/editorialTeam", null, "mailto:amgiraldoni@infomed.sld.cu"]}